Market News / Story
Oncopeptides AB (publ) (ONCO) Reports BBB Penetration in First GBM Patients
·
Oncopeptides said the first three patients in its INSULA WoO study showed intra-tumoral drug levels indicating blood-brain-barrier penetration and good tolerability; one patient has received five monthly doses without major drug-related toxicity. Recruitment continues toward ~10 patients. Material Details #DetailAI Analyst View1BBB penetration shown in first 3 patientsEarly human evidence supports the PDC platform’s ability to reach brain tumors, de-risking the…